An overview of lefamulin for the treatment of community acquired bacterial pneumonia

References

• Sader HS, Paukner S, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67:1170–1175.
   PubMed Web of Science ®Google Scholar
• Dillon C, Guarascio AJ, Covvey JR. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Rev Anti Infect Ther. 2019;17:5–15.
   PubMed Web of Science ®Google Scholar
• Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacother J Hum Pharmacol Drug Ther. 2018;38:935–946.
   Google Scholar
• Perry W, Golan Y. Therapeutic potential of lefamulin in the treatment of community acquired pneumonia. Future Microbiol. 2019 published online 2019 Jul 23;14:927–939. .
   PubMed Web of Science ®Google Scholar
• Paukner S, Sader HS, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013;57:4489–4495.
   PubMed Web of Science ®Google Scholar
• Sader HS, Biedenbach DJ, Paukner S, et al. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(3):1619–1623.
   PubMed Web of Science ®Google Scholar
• Paukner S, Gruss A, Jensen JS. In vitro activity of lefamulin against sexually transmitted bacterial pathogens. Antimicrob Agents Chemother. 2018;62:e02380–17.
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Paukner S, Golparian D, et al. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and Effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(11):e01497–17.
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Jensen JS, Waites KB. New horizons in mycoplasma genitalium treatment. J Infect Dis. 2017;216(suppl 2):S412–9.
   PubMedGoogle Scholar
• Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57(5):2087–2094.
   PubMed Web of Science ®Google Scholar
• Sordé R, Falcó V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011;171(2):166–172.
   PubMedGoogle Scholar
• Said MA, Johnson HL, Nonyane BAS, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273.
   PubMed Web of Science ®Google Scholar
• Torres A, Cillóniz C, Blasi F, et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018;137:6–13.
   PubMed Web of Science ®Google Scholar
• Torres A, Blasi F, Peetermans WE, et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–1079.
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097–1108.
   PubMed Web of Science ®Google Scholar
• Postma DF, van Werkhoven CH, van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–1323.
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200:e45–e67.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–E59.
   PubMed Web of Science ®Google Scholar
• Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci. 2007;333:161–167.
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2006;42:788–797.
   PubMed Web of Science ®Google Scholar
• Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48:1596–1600.
   PubMed Web of Science ®Google Scholar
• Cherazard R, Epstein M, Doan T-L, et al. Antimicrobial resistant streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. 2017;24:e361–9.
   PubMed Web of Science ®Google Scholar
• Schroeder MR, Stephens DS. Macrolide resistance in streptococcus pneumoniae. Front Cell Infect Microbiol. 2016;6:98.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Yin Y. Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med. 2016;37:829–838.
   PubMed Web of Science ®Google Scholar
• Haran JP, Volturo GA. Macrolide resistance in cases of community-acquired bacterial pneumonia in the emergency department. J Emerg Med. 2018;55(3):347–353.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Food and Drug Administration; 2016 [cited 2020 Jan 4]. Available from: https://www.fda.gov/media/119537/download
   Google Scholar
• Taboada M, Melnick D, Iaconis JP, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2016;71:862–870.
   PubMed Web of Science ®Google Scholar
• Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19:1503–1509.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Cillóniz C, Torres A. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. Expert Opin Investig Drugs. 2017;26:1239–1248.
   PubMed Web of Science ®Google Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Betthauser KD. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis. 2019;32(2):169–175.
   PubMed Web of Science ®Google Scholar
• Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from basidiomycetes: VIII. Pleurotus multilus (Fr.) Sacc. and pleurotus passeckerianus pilat. Proc Natl Acad Sci. 1951;37(9):570–574.
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Supplement_3):iii2–4.
   PubMedGoogle Scholar
• Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Invest Drugs. 2010;11(2):182–191.
   PubMedGoogle Scholar
• Yi Y, Fu Y, Dong P, et al. Synthesis and biological activity evaluation of novel heterocyclic pleuromutilin derivatives. Molecules. 2017;22:996.
   Web of Science ®Google Scholar
• Long KS, Hansen LH, Jakobsen L, et al. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob Agents Chemother. 2006;50(4):1458–1462.
   PubMed Web of Science ®Google Scholar
• Paukner S, Riedl R. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb Perspect Med. 2017;7:a027110.
   PubMed Web of Science ®Google Scholar
• Eyal Z, Matzov D, Krupkin M, et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6(1):39004.
   PubMedGoogle Scholar
• Paukner S, Gelone SP, Arends SJR, et al. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015–2016). Antimicrob Agents Chemother. 2019;63:4.
   Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Flamm RK, et al. In vitro activity of lefamulin tested against streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob Agents Chemother. 2016;60(7):4407–4411.
   PubMed Web of Science ®Google Scholar
• Waites KB, Crabb DM, Duffy LB, et al. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother. 2017;61(2):e02008–16.
   PubMed Web of Science ®Google Scholar
• Wicha WW, Strickmann DB, Paukner S. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2019;74(Suppl 3):iii11–8.
   PubMedGoogle Scholar
• Wicha WW, Prince WT, Lell C, et al. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother. 2019;74(Suppl3):iii19–26.
   PubMedGoogle Scholar
• Zeitlinger M, Schwameis R, Burian A, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71(4):1022–1026.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wicha WW, Bhavnani SM, et al. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. J Antimicrob Chemother. 2019;74(Suppl 3):iii27–34.
   PubMedGoogle Scholar
• Wicha WW, Craig WA, Andes D. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. J Antimicrob Chemother. 2019;74(Suppl3):iii5–10.
   PubMedGoogle Scholar
• Bhavnani SM, Zhang L, Hammel JP, et al. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. J Antimicrob Chemother. 2019;74(Suppl3):iii35–41.
   PubMedGoogle Scholar
• Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP). Nabriva Therapeutics. [cited 2020 Jan 4]. Available from: https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-receives-us-fda-approval-xenleta
   Google Scholar
• File TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase iii lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69:1856–1867.
   PubMed Web of Science ®Google Scholar
• Alexander E, Goldberg L, Das A, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019 Sep 27;322:1661. Epub ahead of print.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves new antibiotic to treat community-acquired bacterial pneumonia [press release]. Rockville, MD: FDA; 2019 Aug 19; [cited 2020 Jan 4]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia
   Google Scholar
• Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin. Nabriva Therapeutics. [cited 2019 Aug 6]. Available from: https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-announces-european-medicines-agency-ema
   Google Scholar